Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis

Journal of Gastrointestinal and Liver Diseases

Volumn 26, Issue 1, 2017, Pages 59-67

  Elgebaly, Ahmed ^a   Radwan, Ibrahim A I ^b   Aboelnas, Mohamed M ^c   Ibrahim, Hamza H ^d   Eltoomy, Moutaz F M ^e   Atta, Ahmed A ^f   Mesalam, Hend A ^a   Sayed, Alaa A ^g   Othman, Amr A ^d  

^a AL AZHAR UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d Alexandria University Faculty of Pharmacy   (Egypt)

^e UNIVERSITY OF SADAT CITY   (Egypt)

^f Cairo University   (Egypt)

^g BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Meta analysis; Non alcoholic fatty liver disease; Resveratrol; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; RESVERATROL; TRIACYLGLYCEROL; ANTIOXIDANT; BIOLOGICAL MARKER; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEAD CIRCUMFERENCE; HISTOLOGY; HUMAN; INSULIN BLOOD LEVEL; LIVER FIBROSIS; LIVER INJURY; META ANALYSIS; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; METABOLISM; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; STATISTICAL BIAS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIAS; BIOMARKERS; BLOOD GLUCOSE; CYTOKINES; HUMANS; LIPIDS; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STILBENES;

EID: 85015793922     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.261.ely     Document Type: Review

References (33)

1. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012;36:815-823. doi:10.1111/apt.12046
2. Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag 2007;3:1153–1163.
3. Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998;114:842–845. doi:10.1016/S0016-5085(98)70599-2
4. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010;52:1836–1846. doi:10.1002/hep.24001
5. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011;26:565-576. doi:10.1177/0884533611419668
6. Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One 2014;9:e111808. doi:10.1371/journal.pone.0111808
7. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612–622. doi:10.1016/j.cmet.2011.10.002
8. Bishayee A, Waghray A, Barnes KF, et al. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 2010;27:1080–1091. doi:10.1007/s11095-010-0144-4
9. Gülçin İ. Antioxidant activity of food constituents: an overview. Arch Toxicol 2012;86:345–391. doi:10.1007/s00204-011-0774-2
10. Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2092-2103. doi:10.1016/j.cgh.2014.02.024
11. Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis 2015;47:226-232. doi:10.1016/j.dld.2014.11.015
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097. doi:10.1371/journal. pmed.1000097
13. Green S, Higgins PT, Alderson P, et al. Assessing risk of bias in included studies. In: Higgins JP, Gree S. (eds.). Cochrane Handbook for Systematic Reviews of Interventions. Part 2: General methods for Cochrane reviews. 2011.
14. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403–408. doi:10.1136/gut.2005.069153
15. Altman DG, Bland JM. Standard deviations and standard errors. BMJ 2005;331:903. doi:10.1136/bmj.331.7521.903
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634. doi:10.1136/bmj.316.7129.469
17. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113–2126. doi:10.1002/sim.1461
18. Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, et al. Placebo-controlled, randomised clinical trial: high- dose resveratrol treatment for nonalcoholic fatty liver disease. Scand J Gastroenterol 2016;51:456-464. doi:10.3109/00365521.2015.1107620
19. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014;34:837–843. doi:10.1016/j.nutres.2014.09.005
20. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337–342. doi:10.1038/nature05354
21. Chachay VS, Kirkpatrick CMJ, Hickman IJ, Ferguson M, Prins JB, Martin JH. Resveratrol--pills to replace a healthy diet? Br J Clin Pharmacol 2011;72:27–38. doi:10.1111/j.1365-2125.2011.03966.x
22. Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan African Med J 2009;3:17.
23. Krige JE, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system: portal hypertension-2. Ascites, encephalopathy, and other conditions. BMJ 2001;322:416–418. doi:10.1136/bmj.322.7283.416
24. AboZaid OA, AbdEl-hamid OM, Atwa SA. Biochemical alterations of resveratrol on oxidative stress in experimental induced non - alcoholic fatty liver disease in rats. Benha Vet Med J 2015;28:166–177.
25. Schmatz R, Perreira LB, Stefanello N, et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 2012;94:374-383. doi:10.1016/j.biochi.2011.08.005
26. Chang Y, Jung HS, Yun KE, et al. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease. Obesity (Silver Spring) 2016;24:1996-2003. doi:10.1002/oby.21580
27. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012;107:202– 210. doi:10.1017/S0007114511002753
28. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712–716. doi:10.1038/nature06261
29. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665–668. doi:10.1126/science.271.5249.665
30. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372–1379. doi:10.1111/j.1572-0241.2007.01774.x
31. Seo YY, Cho YK, Bae JC, et al. Tumor Necrosis Factor-α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinol Metab (Seoul) 2013;28:41-45. doi:10.3803/EnM.2013.28.1.41
32. Li L, Hai J, Li Z, et al. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014;63:166–173. doi:10.1016/j.fct.2013.08.036
33. Choi fect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 2014;37:1169–1176. doi:10.1007/s12272-014-0347-z